

A RESEARCH
REPORT
FOR XYX
PHARMACEUTICAL

XYZ
COMPANY
LOGO



New Cancer Immunotherapy Markets

Nobel Prize Edition.

How Disruptive Technology Will Change Therapeutics.

Including Market Forecasts for Immuno-Oncology Therapeutics with Executive and Consultant Guides and a Complete Listing of Active Company Summaries.

2019 to 2023

Introduction to the Nobel Prize Edition

Welcome to this special Nobel Prize Edition of the Cancer Immunotherapy Research Report. This report is designed to educate and inform readers of the potential of Immuno-oncology to transform cancer therapeutics. The report is written in plain English, it avoids technical jargon, and explains the potential, and potential pitfalls, of this exciting new area. Readers should gain an appreciation of the technology and many of the overlapping technical terms in current use. Readers will also gain an appreciation of the size and growth potential of the market in the various technologies. While the report does put forward predictions, the reader is encouraged to read the report critically and make their own judgements.

This “new” area is well over a decade old but, with the Nobel Prize Award, has reached an important milestone. It signals the transition of the work from an experimental therapy of last resort to a mainstream tool that is ready to take its place alongside the traditional treatments of radiation, chemotherapy and surgery. And one day, maybe sooner than we think, it might replace them all.

Table of Contents

- i. Market Guides 17
 - iA. Situation Analysis..... 18
 - iB. Guide for Executives and Marketing Staff 20
 - iC. Guide for Investment Analysts and Management Consultants..... 21
 - iD. Impact of The Nobel Prize 22
- 1. Introduction and Market Definition 23
 - 1.1 What is Cancer Immunotherapy? 24
 - 1.2 Immunotherapy – the looming cure 25
 - 1.3 Market Definition..... 26
 - 1.3.1 Market Size..... 26
 - 1.3.2 Currency 26
 - 1.3.3 Years 26
 - 1.4 Methodology..... 26
 - 1.4.1 Authors..... 27
 - 1.4.2 Sources 27
 - 1.5 U.S. Medical Market and Pharmaceutical Spending - Perspective..... 27
 - 1.5.1 U.S. Expenditures for Pharmaceuticals 28
- 2. Immunotherapy – Guide to Immune Technologies 29
 - 2.0 The Immune System 30
 - 2.0.1 Innate immune system..... 31
 - 2.0.1.1 Surface barriers 31
 - 2.0.1.2 Inflammation 32
 - 2.0.1.3 Complement system..... 33

2.0.1.4 Cellular barriers	33
2.0.1.5 Natural killer cells	34
2.0.2 Adaptive immune system.....	35
2.0.2.1 Lymphocytes.....	35
2.0.2.2 Killer T cells	35
2.0.2.3 Helper T cells	37
2.0.2.4 Gamma delta T cells	38
2.0.2.5 B lymphocytes and antibodies	38
2.0.3 Tumor immunology – the immune surveillance system	40
2.1 Immuno Oncology Technologies	42
2.1.1 Monoclonal Antibodies	42
2.1.1.1 Outlook for Monoclonal Antibodies.....	46
2.1.1.2 Companies with Monoclonal Antibodies in their Pipeline	46
2.1.2 Cancer vaccines	48
2.1.2.1 Outlook for Cancer Vaccines	49
2.1.2.2 Companies with Cancer Vaccines in their Pipeline	49
2.1.3 Cytokines	50
2.1.3.1 Outlook for Cytokines.....	50
2.1.3.2 Companies with Cytokines in their Pipeline	50
2.1.4 Cell Based Therapies	51
2.1.4.1 Outlook for Cell Based Therapies	53
2.1.4.2 Companies with Cell Based Therapies in their Pipeline	54
2.1.5 Inhibitors/Agonists	56
2.1.5.1 Outlook for Inhibitors/Agonists.....	56
2.1.5.2 Companies with Inhibitors/Agonists in their Pipeline	56
2.1.6 Antibody Drug Conjugates	58
2.1.6.1 Outlook for Antibody Drug Conjugates	59

2.1.6.2 Companies with Antibody Drug Conjugates in their Pipeline	59
2.1.7 Others	60
2.1.7.1 Outlook for Other Therapeutics	61
2.1.7.2 Companies with Viral Therapeutics in their Pipeline	61
2.1.7.3 Companies with Other Therapeutics in their Pipeline	61
3. Industry Overview	63
3.1 Market Players – Roles & Impacts	64
3.1.1 Drug manufacturers - Larger/pharmaceutical	64
3.1.2 Drug manufacturers - Generic.....	65
3.1.3 Contract Research and Manufacturing	65
3.1.4 In Vitro Diagnostics Industry	66
3.1.5 Drug Marketing Companies	67
3.1.6 Biotechnology Companies.....	67
3.1.7 Regulatory Bodies	67
4. Market Trends	69
4.1 Factors Driving Growth	70
4.1.1 Outcome potential	70
4.1.2 Fast tracking	71
4.1.3 Funding.....	71
4.1.4 Technology Environment	71
4.1.5 Target Solutions	71
4.2 Factors Limiting Growth.....	73
4.2.1 Cost of Treatment	73
4.2.2 Clinical Trials Role.....	74
4.2.3 Combinations	74
4.2.4 Protocols.....	74
4.3 Therapeutic Technology Development.....	75

- 4.3.1 Combinations - Issues and Complexity 75
- 4.3.2 Preference for a drug 75
- 4.3.3 Problems of Immunity Engineering..... 76
- 4.3.4 The Role of Cost 76
- 4.3.5 The Disruption Dynamic..... 77
- 4.3.6 CAR-T Cell Therapy 79
- 4.3.7 The Next Five Years 80
- 5. Cancer Immunotherapy Recent Developments 81
 - 5.1 Recent Developments – Importance and How to Use This Section 82
 - 5.1.1 Importance of These Developments..... 82
 - 5.1.2 How to Use This Section..... 82
 - 5.2 Cancer ‘vaccine’ eliminates tumors in mice 82
 - 5.3 Iovance Rides The T-Cell Wave 83
 - 5.4 Overcoming the Current Limitations of Cancer Immunotherapy..... 85
 - 5.5 Startup focused on cell therapy gets acquired 86
 - 5.6 Positive results in pre-clinical trials for Imugene’s cancer vaccine..... 87
 - 5.7 Celsion Corporation OPTIMA Study Continues..... 88
 - 5.8 Regeneron and bluebird bio to Collaborate on Cancer Immunotherapy..... 89
 - 5.9 Sangamo bulks up in cell therapy with TxCell acquisition 90
 - 5.10 BI dives deeper into cancer immunotherapy with new acquisition 91
 - 5.11 Innovest Global Acquires Stake in StemVax Therapeutics 92
 - 5.12 Eli Lilly Acquires Pegilodecakin, Potential Immunotherapy Now in Phase 3 Trial..... 93
 - 5.13 FDA Grants Breakthrough Therapy Designation to Lenvima-Keytruda Combo..... 93
 - 5.14 FDA Grants Fast Track Designation to Galinpepimut-S for Treating Multiple Myeloma..... 95
 - 5.15 BioLineRx Initiates Phase 1/2a Trial Testing AGI-134 in Metastatic Solid Tumors 95
 - 5.16 FDA OKs Phase 1 Trial to Test Celyad’s Donor-derived CAR T-cell Therapy in Colorectal Cancer..... 96
 - 5.17 Vyriad Expands Phase 1 Trial to Test Voyager-V1 in Combination with Bavencio for Colorectal Cancer . 97

5.18 FDA Expedites Tecentriq-Avastin Combo for Most Common Liver Cancer 98

5.19 Immunotherapy Use Can Double Survival Rate of Melanoma Patients with Brain Metastasis 98

5.20 FDA Grants Priority Review to Keytruda-Chemo Combo for Metastatic NSCLC 100

5.21 FDA Approves Phase 2 Trial Testing AIVITA’s Vaccine for Aggressive Brain Cancer..... 101

5.22 Immunotherapy Candidate M7824 Effective in Advanced Lung Cancer Patients..... 101

5.23 Apogenix Prepares Submission for Conditional Marketing Authorization in Europe..... 102

5.24 Immunotherapy Leads to Complete Response in Advanced Breast Cancer Patient 103

5.25 Keytruda Beats Chemo at Increasing NSCLC Patients’ Survival, Phase 3 Trial Shows 104

5.26 CBT Pharmaceuticals and CrystalGenomics Announce Partnership..... 105

5.27 New cancer vaccine against melanoma has 100% success rate 106

6. Profiles of Key Immunotherapy Companies 108

 10X Genomics 109

 A. Menarini 110

 AbbVie..... 111

 Ablynx 113

 Adaptimmune Therapeutics PLC..... 114

 ADC Therapeutics..... 115

 Aduro Biotech Inc..... 116

 Agenus Inc..... 117

 AIVITA Biomedical..... 118

 Aleta Biotherapeutics 119

 Amgen 120

 Antigen Express Inc..... 121

 Apeiron Biologics 122

 Apogenix GmbH 123

 Aptose Biosciences 124

 Arcus Biosciences Inc. 125

Astrazeneca PLC.....	126
Atara Biotherapeutics	127
Atlas Venture	128
Aurora Biopharma.....	129
Autolus Therapeutics plc.....	130
Beigene Ltd.	131
Bellicum Pharmaceuticals	132
BioLineRx.....	133
BioNTech.....	134
Biovest International Inc.....	135
Bluebird bio.....	136
Bristol-Myers Squibb.....	137
CARsgen Therapeutics	138
CBT Pharmaceuticals.....	139
Celgene	140
Celldex Therapeutics.....	141
Collectis S A	142
Cellular Biomedicine	143
Celsion Corporation	144
Celyad.....	145
Chugai Pharmaceutical Co.	146
Compugen	147
CrystalGenomics	148
Cytomx Therapeutics Inc.....	149
Cytovac A/S	150
Daiichi Sankyo	151
Dendreon	152

Dynavax Technolgy	153
Eisai	154
Eli Lilly and Co.	155
EMD Serono Inc	156
eTheRNA	157
Fate Therapeutics Inc.....	158
Five Prime Therapeutics Inc.....	159
F-star	160
Gadeta.....	161
Galectin Therapeutics	162
Genentech Inc.....	163
Genmab AS.....	164
Gilead Sciences Inc.....	165
GlaxoSmithKline	166
Gliknik Inc.....	166
Globelimmune Inc.....	168
Glycostem	169
Gritstone Oncology, Inc	170
Heat Biologics Inc.....	171
Heidelberg Pharma GmbH	171
Idera Pharmaceuticals, Inc.....	173
Immatics Biotechnologies GmbH.....	174
Immudex	175
Immune Design	176
Immunomedics	177
Imugene	178
Incyte Corporation	179

Inmune Bio Inc.	180
Innate Pharma.....	181
Iovance Biotherapeutics Inc.....	182
iOx Therapeutics	183
iTeos Therapeutics	184
Janssen Global Services (J&J).....	185
Jounce Therapeutics	187
Juno Therapeutics	188
Kite Pharma Inc.....	189
KSQ Therapeutics	190
Life Science Pharmaceuticals	191
MabVax Therapeutics Holdings Inc.....	192
Macrogenics Inc.	193
MedImmune LLC.....	194
Merck & Co., Inc.....	195
Mirati Therapeutics.....	196
Moderna Therapeutics.....	197
Morphosys AG.....	198
Morphotek Inc	199
Myriad RBM	200
Mustang Bio	201
Nanjing Legend Biotech	202
Nantkwest	203
NBE Therapeutics.....	204
Nekonal Oncology	205
Nektar Therapeutics.....	206
Neon Therapeutics.....	207

NewLink Genetics Corp.....	208
Nilogen.....	209
Noile-Immune Biotech.....	210
Northwest Biotherapeutics Inc.....	211
Novartis A G.....	212
Novelogs Biotechnology, Inc.	213
Novo Nordisk	214
OncoPep Inc.....	215
OSE Immunotherapeutics	216
Oxford BioTherapeutics Ltd.	217
Pfizer	218
Pieris Pharmaceuticals.....	220
Pique Therapeutics	220
Progenics.....	222
PsiOxus.....	223
Qiagen.....	224
Recepta Biopharma.....	225
Regen Biopharma Inc.....	226
Regeneron Pharmaceuticals	227
Rift Biotherapeutics	228
Roche Holdings Inc.....	229
Sanofi	230
Seattle Genetics	231
Sellas	232
Sesen Bio	233
Shattuck Labs	234
Siva Therapeutics	235

Sorrento Therapeutics Inc.....	236
SOTIO a.s.....	237
StemVax Therapeutics	238
Surface Oncology	239
Sydys Corporation.....	240
Syndax Pharmaceuticals	241
Takeda Oncology.....	242
TapImmune Inc.	243
TCR2 Therapeutics	244
Tesaro.....	245
TG Therapeutics	246
ThioLogics Ltd.....	247
Tocagen.....	248
Transgene SA.....	249
Unum Therapeutics.....	250
Verastem.....	251
Virttu Biologics	252
Vyriad	253
Xencor Inc.	254
Ziopharm Oncology Inc.....	255
Zymeworks Inc.	256
6.200 Company Pipelines Analysis.....	257
6.200.1 All Companies, Pipeline Activity Summary by Technology and Phases	257
7. Global Market Size.....	260
7.1 Cancer Immunotherapy Global Market Size by Country with Charts.....	261
7.2 Cancer Immunotherapy Global Market Size by Technology with Charts	263
7.3 Cancer Immunotherapy Global Market Size by Cancer with Charts	265

8. Global Market by Technology.....	266
8.1 Monoclonal Antibody Market.....	267
8.1.1 Monoclonal Antibody Market by Country	267
8.2 Cancer Vaccine Market	269
8.2.1 Cancer Vaccine Market by Country with Chart.....	269
8.3 Cytokines Market.....	271
8.3.1 Cytokines Market by Country with Chart.....	271
8.4 Cell Based Market	273
8.4.1 Cell Based Market by Country with Chart	273
8.5 Inhibitor Agonist Market.....	275
8.5.1 Inhibitor Agonist Market by Country with Chart.....	275
8.6 Other Market	277
8.6.1 Other Market by Country with Chart	277
9. Cancer Immunotherapy Market by Cancer Type	279
9.1 Lung Cancers Market	280
9.1.1 Lung Cancers Market by Country	280
9.2 Breast Cancers Market.....	282
9.2.1 Breast Cancers Market by Country with Chart.....	282
9.3 Blood Cancers Market.....	284
9.3.1 Blood Cancers Market by Country with Chart.....	284
9.4 Colorectal Cancers Market.....	286
9.4.1 Colorectal Cancers Market by Country with Chart	286
9.5 Prostate Cancers Market	288
9.5.1 Prostate Cancers Market by Country with Chart	288
9.6 Other Cancers Market.....	290
9.6.1 Other Cancers Market by Country with Chart	290
10. Appendices	292

10.1 FDA Cancer Drug Approvals by Year 293

10.2 Clinical Trials Started 2010 to 2016 294

10.3 Prevalence of Cancer Treatments – 2015 295

Table of Tables

Table 1 List of Cancers by Mortality 25

Table 2 Overview of Innate and Adaptive Immunity..... 31

Table 3 FDA Approved Monoclonal ANTIBODIES in Cancer treatment..... 42

Table 4 Monoclonal Antibody Companies 47

Table 5 Cancer Vaccine Companies..... 49

Table 6 Cytokine Companies 51

Table 7 Cell Based Therapy Companies..... 54

Table 8 Inhibitor/Agonist Companies..... 56

Table 9 Antibody Drug Conjugate Companies..... 60

Table 10 Viral Therapeutics Companies 61

Table 11 Other Therapeutics Companies 61

Table 12 Market Players by Type..... 64

Table 13 Five Factors Driving Growth..... 70

Table 14 Four Factors Limiting Growth 73

Table 15 Pipeline Snapshot, All Companies. Technologies Trials by Phases 258

Table 16 Cancer Immunotherapy Global Market by Country/Region..... 261

Table 17 Cancer Immunotherapy Global Market by Technology..... 263

Table 18 Cancer Immunotherapy Global Market by Cancer 265

Table 19 Monoclonal Antibody Market by Country 267

Table 20 Cancer Vaccine Market by Country 269

Table 21 Cytokines Market by Country 271

Table 22 Cell Based Market by Country 273

Table 23 Inhibitor Agonist Market by Country 275

Table 24 Other Market by Country 277

Table 25 Lung Cancers Market by Country..... 280

Table 26 Breast Cancers Market by Country 282

Table 27 Blood Cancers Market by Country 284

Table 28 Colorectal Cancers Market by Country 286

Table 29 Prostate Cancers Market by Country..... 288

Table 30 Other Cancers Market by Country 290

Table of Figures

Figure 1 Pharmaceutical Expenditures 2010 to 2020 (\$Billion) 28

Figure 2 Helper T Cell Roles 37

Figure 3 Antibody Diagram 39

Figure 4 Macrophages attack a Cancer Cell 40

Figure 5 CAR-T Clinical Trials 52

Figure 6 Cell Therapy Trial Results..... 53

Figure 7 Antibody Drug Conjugate Diagram 58

Figure 8 Growth rates of IO Technologies 80

Figure 9 Technology Trials by Phase 259

Figure 10 Market Size by Country - Key Countries 262

Figure 11 Global Market by Country 262

Figure 12 Chart of Global Market by Technology.....	263
Figure 13 Growth Rates of Technology Segments	264
Figure 14 Chart of Global Market by Cancer	265
Figure 15 Chart – Monoclonal Antibody Market by Country	268
Figure 16 Chart – Cancer Vaccine Market by Country	270
Figure 17 Chart – Cytokines Market by Country	272
Figure 18 Chart - Cell Based Market by Country	274
Figure 19 Chart – Inhibitor Agonist Market by Country	276
Figure 20 Chart – Other Market, Global Size.....	278
Figure 21 Chart – Lung Cancers Market by Country.....	281
Figure 22 Chart – Breast Cancers Market by Country	283
Figure 23 Chart – Blood Cancers Market by Country	285
Figure 24 Chart - Colorectal Cancers Market by Country.....	287
Figure 25 Chart – Prostate Cancers Market by Country.....	289
Figure 26 Chart – Other Cancers Market by Country	291
Figure 27 FDA Cancer Drug Approvals by Year.....	293
Figure 28 Clinical Trials for Immunotherapy by Year	294
Figure 29 Pie Chart of Prevalence of Cancer Treatments	295